Clinical Trials in China / NCT07848945
Starting soon
Phase 1
Phase I Study of JY1001 Injection
NCT07848945 · tracked via the Priya Life Science China tracker
Condition(s) studied
Pain After Surgery
Investigational drug(s) / intervention(s)
JY1001Placebo
JY1001: Participants will receive a single dose of JY1001 (10 mg, 20 mg, 40 mg, 80 mg, 160 mg, 320 mg) via IV at Day 1
Placebo: Participants will receive a single dose of placebo via IV at Day 1
Study summary
The goal of this dose esclation study is to evaluate the safety, tolerability, and PK characteristicsafter of a single dose of JY1001 injection in healthy participants. A total of 6 cohorts are planned to be evaluated. Each cohort will enroll 8 participants to receive JY1001 or placebo in 3:1 ratio.
Eligibility
Inclusion Criteria:
* Healthy male or female adult participants
* Men ≥50kg, women ≥45kg, and body mass index (BMI) 19-28 kg/m² (inclusive)
Exclusion Criteria:
* With any disease that the investigator judges will take risk to participants or affect the evaluation of the study.
Primary outcome measure(s)
- Adverse events (AEs) — Day 1 to Day 4
Incidence of Adverse events (AEs)
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital | Chengdu | Sichuan |
More Jemincare trials in China
Other trials for the same condition
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07848945 on ClinicalTrials.gov ↗ ← All trials in China